Related content

Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients

By                

Oncology Letters, Vol. 10, Iss. 3, 2015-01 ,pp. : 1882-1888

Spandidos Publications

Access to resources Recommend Favorite

PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms

By                        

International Journal of Oncology, Vol. 44, Iss. 2, 2014-01 ,pp. : 548-556

Spandidos Publications

Access to resources Recommend Favorite

Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules

By              

Oncology Letters, Vol. 9, Iss. 6, 2015-01 ,pp. : 2633-2638

Spandidos Publications

Access to resources Recommend Favorite

BRAF mutation is not predictive of long‐term outcome in papillary thyroid carcinoma

By  

Cancer Medicine, Vol. 4, Iss. 6, 2015-06 ,pp. : 791-799

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intratumor heterogeneity of BRAF V600E mutation in lung adenocarcinomas

By                  

Experimental and Therapeutic Medicine, Vol. 9, Iss. 5, 2015-01 ,pp. : 1719-1722

Spandidos Publications

Access to resources Recommend Favorite